Evidence map›Paper›PMID 38726720›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024

Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document.

Philippe Garot, Marie-Claude Morice, Dominick J Angiolillo, Josep Rodés- Cabau, Duk-Woo Park, Nicolas M Van Mieghem, Jean-Philippe Collet, Martin B Leon, Gunasekaran Sengottuvelu, Antoinette Neylon and 21 more

Abstract readConsensus Statement
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. VARC-HBR criteria validation in TAVI patients on oral anticoagulation.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Trial
  2. Review
  3. Review
  4. Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  5. Review
  6. An ongoing quest to discern the optimal antithrombotic therapy after TAVI.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Philippe GarotInstitut Cardiovasculaire Paris-Sud (ICPS), Hôpital privé Jacques Cartier, Ramsay-Santé, Massy, France.
Marie-Claude MoriceInstitut Cardiovasculaire Paris-Sud (ICPS), Hôpital privé Jacques Cartier, Ramsay-Santé, Massy, France.
Dominick J AngiolilloDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Josep Rodés- CabauQuebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
Duk-Woo ParkDivision of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Nicolas M Van MieghemDepartment of Cardiology, Erasmus University Medical Center, Thoraxcenter, Rotterdam, the Netherlands.
Jean-Philippe ColletSorbonne Université, ACTION Study Group, INSERM UMR_S 1166, Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France.
Martin B LeonColumbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USA and Cardiovascular Research Foundation, New York, NY, USA.
Gunasekaran SengottuveluDepartment of Cardiology, Apollo Hospitals, Chennai, Tamil Nadu, India.
Antoinette NeylonInstitut Cardiovasculaire Paris-Sud (ICPS), Hôpital privé Jacques Cartier, Ramsay-Santé, Massy, France.
Jurrien M Ten BergCardiovascular Research Institute Maastricht, Maastricht, the Netherlands.
Darren MylotteGalway University Hospital and University of Galway, Galway, Ireland.
Didier TchétchéGroupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.
Mitchell W KrucoffDuke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Michael J ReardonDepartment of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, USA.
Nicolo PiazzaMcGill University Health Centre, Montreal, QC, Canada.
Michael J MackBaylor Scott & White Heart Hospital Plano, Plano, TX, USA.
Philippe GénéreuxGagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, USA.
Raj MakkarSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Yohei OhnoDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Shuichi MochizukiPharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.
Yuko ShiraiNotified body 1639, SGS, Antwerp, Belgium.
Ryosuke MatsumaraPharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.
Yu JinNotified body 1639, SGS, Antwerp, Belgium.
John G WebbDepartment of Cardiology, St. Paul's Hospital and University of British Columbia, Vancouver, BC, Canada.
Donald E CutlipCardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA and Baim Clinical Research Institute, Boston, MA, USA.
Mao ChenDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Ernest SpitzerThoraxcenter, Erasmus University Medical Center, and Cardialysis, Clinical Trial Management and Core Laboratories, Rotterdam, the Netherlands.
Roxana MehranIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Davide CapodannoCardiovascular European Research Center (CERC), Massy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<span style="font-size:12pt"><span style="font-family:Aptos,sans-serif">The identification and management of patients at high bleeding risk (HBR) undergoing transcatheter aortic valve implantation (TAVI) are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. VARC-HBR is an initiative of the CERC (Cardiovascular European Research Center), aiming to develop a consensus definition of TAVI patients at HBR, based on a systematic review of the available evidence, to provide consistency for future clinical trials, clinical decision-making, and regulatory review. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI.</span></span>.

Indexed as

HemorrhageTranscatheter Aortic Valve ReplacementAortic ValveAortic Valve StenosisHumansRisk AssessmentRisk Factors

Identifiers

PMID38726720
PMCPMC11067726

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.